Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$253K Buy
1,381
+236
+21% +$43.5K 0.01% 1208
2025
Q4
$202K Sell
1,145
-2,195
-66% -$359K 0.01% 1284
2025
Q3
$468K Buy
+3,340
New +$451K 0.02% 772
2024
Q4
Sell
-13,294
Closed -$2.58M 1562
2024
Q3
$2.58M Sell
13,294
-624
-4% -$131K 0.01% 1384
2024
Q2
$3.23M Buy
+13,918
New +$3.02M 0.01% 1149
2024
Q1
Sell
-15,981
Closed -$3.74M 3866
2023
Q4
$4.14M Buy
15,981
+658
+4% +$162K 0.01% 1138
2023
Q3
$3.94M Buy
15,323
+4,235
+38% +$1.13M 0.01% 1068
2023
Q2
$3.16M Buy
+11,088
New +$3.3M 0.1% 181

Other funds holding BIIB

GTS Securities's BIIB Position: Q1 2026 in Review

GTS Securities increased its Biogen (BIIB) stake by 21% in Q1 2026, buying an estimated $43.5K and bringing the position to 1,381 shares worth $253K. The position accounts for 0.01% of the portfolio, ranked #1208.

GTS Securities first reported a position in BIIB in Q2 2023 and has held it in 8 quarters since. The position peaked at $4.14M in Q4 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • GTS Securities held 1,381 shares of Biogen worth $253K as of Q1 2026.
  • GTS Securities bought 236 Biogen shares in Q1 2026, an estimated $43.5K.
  • Biogen made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1208 holding.
  • GTS Securities first reported a position in Biogen in Q2 2023 and has held it in 8 quarters since.
  • GTS Securities's Biogen position peaked at $4.14M in Q4 2023.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.